Study of Ear Comfort Ear Drops to Treat AOE Cases Compared to DexOtic & Otidin(R)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Phase II 3 arm double blinded clinical study, to evaluate pain killing and healing time of Botanical Ear Drops, Ear Comfort™, in Severe External Ear Infection (AOE) patients in comparison to Dex-Otic® and Otidin®.
Study Outcome (hypothesis): if Ear Comfort™ proves to perform as well as Dex-Otic, then ENT's and family doctors will have a botanical non-antibiotic product that does not promote the formation of antibiotic-resistant infections and may be given to anti-biotics sensitive patients.
Ear comfort™ is pharmacologically stable for at least 3 years on the shelves.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Otitis Externa |
Device: Natural Ear Comfort(TM), a botanical ear drops product |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Phase II 3 Arm Double Blinded Clinical Study Evaluating the Pain Killing and Healing Time of Botanical Ear Drops, Ear Comfort(TM), in Severe External Ear Infection (AOE) Patients, Compared to Dex-Otic(R) and Otidin(R) |
- Ear Comfort(TM) kills pain in AOE patients within how many hours? [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]Comparing Ear Comfort(TM) botanical ear drops performance in killing pain in AOE patients to Dex-Otic and Otidin Will be measured by Pain Scores on the Visual Analog Scale. The patients will score their pains on a patient's diary document. A professional medical statitician expert will make the anlysis.
- Does Ear Comfort(TM) heal the inflamation in AOE patients? [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]Performance of Ear Comfort(TM) ear drops, Dex-Otic and Otidin in healing AOE patients ear will be measured by: - reducing microbiological load, patient's compliance and ENT expert/s check of the year during the treatment period and 7 days after stopping the treatment.
| Estimated Enrollment: | 75 |
| Study Start Date: | July 2011 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 2 Dex-Otic ear drops
Dex-Otic(R) ear drops are used for pain relief and treating ears of AOE patients. It contains: Dexamethasone Sodium Phosphate 1 mg; Neomycin sulfate 5 mg; Polymyxin B sulfate 10,000 units. It
|
Device: Natural Ear Comfort(TM), a botanical ear drops product
Ear Comfort(TM): active ingredients - Thyme essential oil & Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant. Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units. Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water. Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin. Other Names:
|
|
Experimental: 3 Ear Comfort(TM) ear drops
Natural Ear comfort(TM) ear drops contains Chamomile extract and Thyme oil in anhydrous glycerin for pain relief and ear healing.
|
Device: Natural Ear Comfort(TM), a botanical ear drops product
Ear Comfort(TM): active ingredients - Thyme essential oil & Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant. Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units. Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water. Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin. Other Names:
|
|
Active Comparator: 1 Otidin(R) ear drops
Otidin(R): Ear drops containing Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin for pain relief in AOE patients.
|
Device: Natural Ear Comfort(TM), a botanical ear drops product
Ear Comfort(TM): active ingredients - Thyme essential oil & Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant. Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units. Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water. Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin. Other Names:
|
Detailed Description:
Severe External Ear Infection (AOE) also known as Swimmer's ear, is an abundant microbiological contamination disease of the outer ear canal. It causes severe pains and accumulation of fluids in the ear. In some cases it may compromise the hearing. Swimming in contaminated water or cleaning the ear with a hard subject are only two examples of what may cause AOE. The main Pathogenes causing the disease are Gram negative of which Pseudomonas aeruginosa is the most abundant. Occasionally it is a fungoid contamination with Aspergillus Niger being the most abundant.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with AOE.
- AOE patient determined by ear canal obstruction, exudates and pain.
- Males and Females between 18 and 65 years of age.
- Patients willing to refrain from using any ear drops products for the entire duration of the study. - - Subjects are willing to use the full 4 steps protocol
- Written informed consent has been obtained.
Exclusion Criteria:
- Known allergy or sensitivity to Chamomile extract or essential oils.
- Injury to tympanic membrane.
- Medical or psychiatric conditions that affect the patient's ability to give informed consent, or complete the study.
- Pregnant or lactating females.
- Use of ear drops or antibiotic or analgesic medications within the last 4 weeks prior to enrolment to the study.
- Other known diseases, including severe allergy, chronic liver or kidney disease, malignancy or contagious diseases, such as HIV or hepatitis.
- Alcohol or drug abuse, according to assessment by the investigator.
- Participation in other clinical trial within the last 30 days.
Contacts and Locations| Israel | |
| "Maccabi" Clinic | Recruiting |
| Gedera, Israel | |
| Contact: Dan Guttman, MD 972 52 7777730 dan1966@netvision.net.il | |
| Principal Investigator: Dan Guttman, ENT MD | |
| Principal Investigator: | Dan Guttman, MD | Maccabi Healthcare Services, Israel |
More Information
No publications provided
| Responsible Party: | Assuta Hospital Systems |
| ClinicalTrials.gov Identifier: | NCT01584271 History of Changes |
| Other Study ID Numbers: | 2011058 |
| Study First Received: | April 5, 2012 |
| Last Updated: | December 12, 2012 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Assuta Hospital Systems:
|
AOE Ear Comfort Dex Otic Otidin |
Additional relevant MeSH terms:
|
Otitis Externa Otitis Ear Diseases Otorhinolaryngologic Diseases Polymyxin B Dexamethasone acetate Dexamethasone Dexamethasone 21-phosphate BB 1101 Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Anti-Inflammatory Agents |
Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013